GLP-1 RAs, such as semaglutide and tirzepatide, demonstrated consistent benefits across both obese and nonobese populations while addressing concerns about rapid or excessive weight loss, which could undermine the hemodynamic and survival advantages linked to obesity. This evidence concerns the gene GLP1R and obesity disorder.